Stryker Corporation (SYK) VP Sells $23,169.00 in Stock
Stryker Corporation (NYSE:SYK) VP M Kathryn Fink sold 150 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $154.46, for a total value of $23,169.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Stryker Corporation (SYK) traded down $3.51 during mid-day trading on Monday, hitting $152.36. The company had a trading volume of 1,351,039 shares, compared to its average volume of 1,182,374. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. The stock has a market cap of $57,020.00, a P/E ratio of 24.70, a PEG ratio of 2.45 and a beta of 0.78. Stryker Corporation has a 52-week low of $111.22 and a 52-week high of $160.62.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.39 EPS. sell-side analysts expect that Stryker Corporation will post 6.47 EPS for the current fiscal year.
SYK has been the topic of several recent analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $155.00 price target on shares of Stryker in a research note on Friday, September 1st. Argus reaffirmed a “buy” rating and issued a $160.00 price target on shares of Stryker in a research note on Tuesday, August 29th. Zacks Investment Research lowered Stryker from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating and upped their price target for the company from $161.00 to $173.00 in a research note on Thursday, November 16th. Finally, Stifel Nicolaus upped their price target on Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the stock. Stryker currently has an average rating of “Hold” and an average price target of $152.10.
Hedge funds have recently bought and sold shares of the stock. Acrospire Investment Management LLC purchased a new stake in Stryker during the 2nd quarter worth about $111,000. Motco boosted its position in shares of Stryker by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 278 shares in the last quarter. San Francisco Sentry Investment Group CA boosted its position in shares of Stryker by 47.8% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 325 shares in the last quarter. Bruderman Asset Management LLC acquired a new position in shares of Stryker during the 2nd quarter worth about $150,000. Finally, James Investment Research Inc. acquired a new position in shares of Stryker during the 2nd quarter worth about $155,000. Hedge funds and other institutional investors own 74.97% of the company’s stock.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.